Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis

Exclusion Criteria

• •Extensive colonic resection or subtotal or total colectomy
• •Presence of an ileostomy or colostomy
• •Moderate to severe anemia
• •A history or evidence of colonic mucosal dysplasia
• •Pregnant or lactating
• •Significant uncontrolled co-morbidity, such as neurological, cardiac, pulmonary, renal, hepatic, endocrine, or gastrointestinal (GI) disorders
• •Significant screening ECG abnormalities, including evidence of acute myocardial infarction, complete left bundle branch block, second-degree heart block, or complete heart block
• •Poorly controlled diabetes
• •Impaired renal function
• •Impaired hepatic function in the absence of a diagnosis of primary sclerosing cholangitis
• •Positive tests for antibodies indicating active or prior infection with HIV or hepatitis B (HBV) or C (HCV)
• •Positive screening test for latent mycobacterium tuberculosis (TB) infection
• •Demyelinating disease
• •Received any investigational treatment within 12 weeks prior to initiation of study treatment
• •Previous exposure to rhuMAb Beta7